Stocks and Investing
Stocks and Investing
Mon, March 22, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, March 19, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Maintained (ADCT) at Strong Buy with Increased Target to $48 on, Mar 19th, 2021
Robert Burns of HC Wainwright & Co., Maintained "ADC Therapeutics SA" (ADCT) at Strong Buy with Increased Target from $47 to $48 on, Mar 19th, 2021.
Robert has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 1 agrees with Robert's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Konstantinos Aprilakis of "Stifel" Initiated at Hold and Held Target at $42 on, Thursday, December 3rd, 2020
This is the rating of the analyst that currently disagrees with Robert
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $56 on, Wednesday, December 16th, 2020
Contributing Sources